GlassScriptPhysician profile
Layne D Roberts
NPI 1902809205
$1,455.00
in general payments reported to CMS, 2019-2025
24 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $142 · 2021: $177 · 2022: $208 · 2023: $105 · 2024: $345 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $714.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.27 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $194.87 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $166.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $145.15 | 2021-2025 | Ubrelvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.14 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $86.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.30 | 2020-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $55.88 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $48.54 | 2024 | Gvoke Hypopen |
| Medtronic, INC. | $45.22 | 2021-2025 | Inceptiv |
| Astrazeneca Pharmaceuticals LP | $44.03 | 2019-2022 | |
| Mylan Specialty L.P. | $41.09 | 2020-2024 | Yupelri |
| Allergan, INC. | $35.81 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $28.02 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.12 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $25.01 | 2019-2022 | |
| Boston Scientific Corporation | $23.73 | 2019 | |
| Recor Medical INC | $19.21 | 2024 | Paradise Renal Denervation System |
| Pfizer INC. | $18.74 | 2019 | |
| Philips North America LLC | $16.53 | 2024 | (Ck4) Mcot |
| E.R. Squibb & Sons, L.L.C. | $14.40 | 2025 | Cobenfy |
| Shield Therapeutics INC | $14.03 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $12.99 | 2022 | |
| Lucid Diagnostics INC. | $12.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Layne Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.